NERV: Roluperidone's pivotal phase III trial is on track, with results expected next year and strong investor support
The conference highlighted progress in developing roluperidone for negative symptoms of schizophrenia, with a confirmatory phase III trial underway and results expected in the second half of next year. Strong IP protection and robust financial backing support ongoing clinical and regulatory efforts…